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Amye Kenall1*, Scott Edmunds2, Laurie Goodman2, Liz Bal1, Louisa Flintoft3, Daniel R Shanahan1 and Tim Shipley4How easy is it to reproduce or replicate the findings of a
published paper? In 2013 one researcher, Phil Bourne,
asked just this. How easy would it be to reproduce the
results of a computational biology paper? [1]. The an-
swer: 280 hours. Such a number is surprising, given the
theoretical reproducibility of computational research
and given Bourne was attempting to reproduce work
done in his own lab. Now at the National Institutes of
Health (NIH) as Associate Director of Data Sciences,
Bourne is concerned with the reproducibility of all NIH
funded work, not just his own—and the problem is
large. In addition to work in computational biology (which
theoretically should be more easily reproducible than “wet
lab” work), hallmark papers in cancer through to psych-
ology have been flagged as largely unreproducible [2, 3].
Closer to home, GigaScience has carried out similar work
to quantify reproducibility in their content. Despite being
scrutinized and tested by seven referees, it still took about
half a man-month worth of resources to reproduce the
results reported in just one of the tables [4]. “Reprodu-
cibility” is now increasingly on the radar of funders and
is making its rounds in the wider media as well, with
concerns of reproducibility making headlines at The
Economist [5] and New York Times [6], amongst other
outlets.Why is this important?
It is critical to note that irreproducible work doesn’t
necessarily mean fraud occurred, nor even that the
findings are incorrect; likewise, reproducible research
can still be incorrect. While this key point is well-
understood by most scientists, this is not always easy to
explain to the general public. However, as most re-
search is paid for through tax payers, public trust in
research is essential. We—researchers, funders, and
publishers—must do a better job at communicating this
message to the public. We must better explain that science* Correspondence: amye.kenall@biomedcentral.com
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But we also must develop policies that better support this
process—policies, for example, that promote transparency
and allow for improved verification of research.
Clearly important for clinical research, verification is
equally important for preclinical research, something we
all have an equal stake in. No one can innovate new
drugs overnight, no matter how rich they are, no matter
which doctor they see. Better, more robust preclinical
research benefits us all.1 Our ability to rely on published
data for potential therapeutics is critical, and recently its
reliability has been called into question [7].
One well-publicised example of this was brought to
light in an oncology study of preclinical research find-
ings in which researchers were able to confirm only
11 % of the findings [8, 9]. Although the relevance of
more robust research is clear in the area of oncology, it
is also important for more exploratory research that might
never make it to the preclinical setting. Funding and time
are both increasingly limited, and the waste generated
from follow-up work based on irreproducible research is
high. A recent study by Freedman et al. estimated this at
approximately $28 billion a year for preclinical research in
the United States alone [10].Funder update
The NIH have recently taken bold steps to begin to
tackle the need for better design, more appropriate
analysis, and greater transparency in the conduct and
reporting of research. In January 2014 the NIH an-
nounced they would fund more training for scientists
in data management and restructure their grant review
process to better value other research objects, such as
data [11]. But it is peer review and the editorial policies
and practices of journals that have come under the
greatest scrutiny, and in June 2014 a set of guidelines
for reporting preclinical research were proposed by the
NIH to meet the perceived need for more stringent
standards [12]. These guidelines ask journals to ensure, for
example, that authors have included a minimum set ofticle distributed under the terms of the Creative Commons Attribution License
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been carried out by reviewers, and that authors have been
given enough information to enable animal strains, cell
lines, reagents, and so on, to be uniquely identified re-
agents. (For a full list of requirements, see the NIH Princi-
ples and Guidelines for Reporting Preclinical Research.)
BioMed central author and reviewer checklist
Journals clearly have an important part to play in help-
ing to ensure as far as possible that experimental design
and analysis are appropriate, and that reporting stan-
dards are met. This month BioMed Central will launch
a trial checklist for authors and referees with these
explicit aims.
BioMed Central has long supported transparency in
reporting for both biology and medicine, even working
with Editorial Board Members developing and endorsing
standards such as MIQE-precis [13], and the EQUATOR
Network guidelines, such PRISMA [14]. The trial checklist
builds on these accepted standards and the principles
behind them, formalising, tailoring and standardising
these efforts across journals.
The checklist addresses three areas of reporting: ex-
perimental design and statistics, resources, and avail-
ability of data and materials [15]. Some of the NIH
Guidelines were straightforward to implement, given
they were policies long in place at BioMed Central.
However, we used these new guidelines as an opportun-
ity to ensure that these as well as our long-standing
policies already in place had the best chance of being
adhered to by authors and by reviewers by integrating
them into our internal systems and workflows. Authors
will be asked on submission to confirm that they have
included the information asked for in the checklist or
give reasons for any instances where it is not made
available or not applicable.2 Likewise, reviewers will be
asked to confirm the information has been satisfactorily
reported and reviewed.
This also has the aim of making editors’ jobs more
straightforward. With a clear and simple checklist on
what information to include in the manuscript, less time
should be spent liaising with authors. Plans are also in
place to integrate our new checklist into BioMed Central
Roadshows and Author Workshops (http://roadshow.
biomedcentral.com/), helping to ensure researchers are
made aware of the reporting standards before publication.
BioMed Central is not the first to implement reporting
guidelines, with the Center for Open Science [16]3 and
our colleagues at Nature. [17] also recently announcing
similar initiatives. Implementing reporting guidelines, ra-
ther through a checklist or another means, is not simple.
Exploratory research that does not have the immediate
practical implications of preclinical research often does
not easily adhere to the criteria of reproducibility. For this2reason we are implementing this first as a trial, for which
we will collect feedback and monitor its success.
In the first instance, the checklist will be rolled out on a
small group of select journals: BMC Biology, BMC Neuro-
science, Genome Biology, and GigaScience. In 6 months’
time, we plan to review the data we have collected around
this trial, checking whether reporting has increased and
collating author, editor, and reviewer feedback on the trial,
with the aim to roll out the checklist (with any revisions)
across all BioMed Central journals. We have designed the
checklist to act as an aid to authors, editors, and reviewers
rather than a burden to submission and look forward to
hearing your thoughts as the trial progresses.
Endnotes
1For further discussion of this around clinical trial
transparency and reliability, see Ben Goldacre’s Bad
Pharma.
2To better support our authors in adhering to this
checklist, we have also recently revised our section on data
availability, detailing where authors can deposit their data
and how to cite their data in their manuscript. We also
have in-house staff available to work with authors to find
a home for their data. http://www.biomedcentral.com/
about/editorialpolicies#DataandMaterialRelease
3The Center for Open Science with stakeholders from
research have recently devised an easy to use set of guide-
lines based on eight standards and three levels of adher-
ence. With this checklist, all journals will adhere to level 2
requirements. At present, all BioMed Central journals ad-
here to level 1 requirements. http://www.sciencemag.org/
content/348/6242/1422.figures-only
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